The purpose of this study is to study the safety and tolerability of synthetic PreImplantation Factor (sPIF) in female patients with autoimmune hepatitis. Autoimmune hepatitis is a disease where the patient's immune system produces an inappropriate immune response against their own liver. PreImplantation Factor is a substance that is secreted by viable fetuses during pregnancy. PIF apparently initiates both maternal tolerance preventing the loss/rejection of the fetus. Synthetic PIF (sPIF) successfully translates PIF endogenous properties to pregnant and non-pregnant immune disorders. sPIF was found to be effective in preclinical models of autoimmunity and transplantation (published). Specifically sPIF protected the liver against immune attack. In FDA mandated toxicity studies (mice, dogs), high-dose sPIF administration for 2 weeks followed by 2 weeks observation period demonstrated a high safety profile. Based on those observations the FDA has granted a Fast Track designation for this trial. This study will evaluate the safety, tolerability and the blood level of this synthetic version of this natural compound in the circulation.